The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3764	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3765	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3766	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3767	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3768	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3769	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3770	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3771	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3772	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume to below 500mm after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3773	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990/Gemcitabine resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3774	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990/Gemcitabine resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume to below 300mm after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_4084	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4085	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary adenoma cell line	Cell lineZMTH3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4086	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman prostate carcinoma cell line	Cell lineCT1258	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4087	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineHuman canine soft tissue sarcoma	Cell lineSTSA-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4088	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4089	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary adenoma cell line	Cell lineZMTH3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4090	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman prostate carcinoma cell line	Cell lineCT1258	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4091	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineHuman canine soft tissue sarcoma	Cell lineSTSA-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4092	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result25% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4093	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary adenoma cell line	Cell lineZMTH3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4094	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman prostate carcinoma cell line	Cell lineCT1258	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4095	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineHuman canine soft tissue sarcoma	Cell lineSTSA-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4096	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result95% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4097	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary adenoma cell line	Cell lineZMTH3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result95% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4098	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman prostate carcinoma cell line	Cell lineCT1258	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result95% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4099	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineHuman canine soft tissue sarcoma	Cell lineSTSA-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result95% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4100	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4101	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary adenoma cell line	Cell lineZMTH3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4102	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman prostate carcinoma cell line	Cell lineCT1258	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4103	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineHuman canine soft tissue sarcoma	Cell lineSTSA-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4104	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4105	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary adenoma cell line	Cell lineZMTH3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result25% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4106	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman prostate carcinoma cell line	Cell lineCT1258	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4107	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineHuman canine soft tissue sarcoma	Cell lineSTSA-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4108	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1000 mm compared to control 2500mm after 42 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4109	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 200 mm compared to control 2500mm after 49 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4721	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4722	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4723	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4724	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4725	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4726	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4727	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4728	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4729	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4730	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result65% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4731	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4732	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4733	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4734	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4735	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4763	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4764	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4765	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result75% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4766	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result65% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4767	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4768	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4769	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result75% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4770	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result75% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4771	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4772	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result75% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4773	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4774	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result25% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4788	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4791	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4794	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4797	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4800	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result2% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4803	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4806	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4809	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4812	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4815	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result2% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4818	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4821	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4824	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4827	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4830	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result1% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4833	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4836	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4839	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4842	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4845	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4848	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4851	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4854	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4857	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4860	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineSKOV3	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4863	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4866	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4869	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4872	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4875	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineOVCAR8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4947	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4948	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4949	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4950	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4951	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4952	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result25% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781